Minimal residual disease as the target for immunotherapy of cancer.
Nossal
G J
GJ
Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000601:surgery / Q000628:therapy*; D006801:Humans
D000911:Antibodies, Monoclonal